Human Absorption Study of Liposomal Glucosamine Supplements
Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements
- Glucosamine
- Liposomal Encapsulation
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- TCI Co., Ltd.
- Enrolment target
- 16
- Started
- 21 October 2026
- Main results due
- 31 December 2026
- Study sites
- 1
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- Healthy volunteers can take part.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Adults aged ≥18 years, regardless of sex, who are willing to sign the informed consent form and are able to fully comply with all study procedures. Exclusion Criteria: * Pregnant or breastfeeding women, or individuals who are unwilling to use a physical method of contraception during the study period, such as condoms or an intrauterine device. * Employees of TCI Co., Ltd. and their family members. * Individuals who have regularly taken any supplements or medications containing glucosamine or N-acetylglucosamine (N-acetyl-glucosamine) within 14 days prior to study initiation, defined as use for ≥7 consecutive days. * Individuals with a history of chronic gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), chronic diarrhea, Crohn's disease, celiac disease, bowel control problems/fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, or ulcerative colitis; a history of epilepsy or seizures; liver or kidney disease; malignancy; endocrine disorders; psychiatric disorders; alcohol or substance abuse; or other significant organic diseases, as determined based on medical history. * Individuals with a history of gastrointestinal surgery, organ transplantation, or other major surgery. * Individuals who have experienced acute gastroenteritis within 2 weeks prior to study initiation. * Individuals with a history of allergy to any ingredient in the investigational products. The investigational products contain shrimp- and soy-derived ingredients. * Vegetarians, as the glucosamine used in this study is derived from shrimp.
What this study is about
In the sponsor’s own words, from the registry.
The objective of this study is to evaluate the effects of liposomal encapsulation using different ratios of gum arabic and lecithin on the bioavailability of a liquid glucosamine supplement in humans.
Study sites(1)
TCI Co., Ltd
Taipei, Taiwan
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07843342. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me